XPeng Inc (NYSE:XPEV) could be the dark horse in the EV race

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Chinese stocks are gapping higher this morning and unlike U.S tech stocks so far are holding those gains. 

The China re-opening, post stringent Covid lockdowns appears like it will stick this time and that’s good for Chinese names. XPeng Inc (NYSE:XPEV) reported vehicle deliveries for December of 11,292 vehicles representing a 94% increase over November. Unlike TSLA which disappointed, XPeng Inc (NYSE:XPEV) surprised positively. XPEV is currently trading at 10.145USD with a gain of $0.205 (2.06%).

XPEV Stock Chart

Technically, XPEV is making a nice flag pattern. It’s consolidating nicely with a higher low and given how much it sold off in 2022 has significant bounce potential.